Veritas In Silico Inc. (TYO:130A)
Japan · Delayed Price · Currency is JPY 426.00
-4.00 (-0.93%)
Aug 27, 2026, 3:30 PM JST
Veritas In Silico Revenue
Veritas In Silico had revenue of 18.35M JPY in the quarter ending June 30, 2026, a decrease of -4.92%. This brings the company's revenue in the last twelve months to 84.42M, down -30.84% year-over-year. In the year 2025, Veritas In Silico had annual revenue of 91.14M, down -53.18%.
Revenue (ttm)
84.42M
Revenue Growth
-30.84%
P/S Ratio
33.04
Revenue / Employee
n/a
Employees
19
Market Cap
2.79B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 91.14M | -103.50M | -53.18% |
| Dec 31, 2024 | 194.64M | -165.71M | -45.99% |
| Dec 31, 2023 | 360.36M | 181.56M | 101.54% |
| Dec 31, 2022 | 178.80M | 119.47M | 201.37% |
| Dec 31, 2021 | 59.33M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 13.64B |
| Kohjin Bio | 4.69B |
| Human Metabolome Technologies | 1.42B |
| Kringle Pharma | 342.21M |
| D. Western Therapeutics Institute | 247.00M |
| Ribomic | 7.50M |
| FunPep Company | 1.00M |